Back to News
Oct 15, 2025 4:00 PM

Omeros Stock Skyrockets After Novo Nordisk Strikes $2.1B Rare Disease Drug Deal

Biotech breakthroughs are reshaping the pharmaceutical landscape, sparking lucrative deals and redefining the future of rare disease treatment. Omeros Corporation (NASDAQ:OMER) stock is rallying on Wednesday, with a session volume of 89.21 million versus the average volume of 1.11 million, as per data from Benzinga Pro.

Novo Nordisk A/S (NYSE:NVO) and Omeros on Wednesday announced an asset purchase and license agreement for the candidate drug zaltenibart (formerly OMS906) for rare blood and kidney disorders.

Under the terms of the agreement, Novo Nordisk will be granted exclusive global rights to develop and commercialize zaltenibart in all indications.

Omeros can receive $340 million in upfront and near-term milestone payments, up to $2.1 billion ...